Table 3.
(a) First-Line Treatments Recorded for Patients with ND AML and (b) Treatments Recorded Prior to First Diagnosis of R/R AML in Patients with R/R AML
| (a) | ||||||||
| Therapy | All Patients with ND AML (N = 853) | FLT3WT at Initial Diagnosis (N = 432) | FLT3MUT at Initial Diagnosis (N = 109) | Unknown FLT3 Mutation Status (N = 312) | ||||
| Patients,a n (%) | Mean (SD) Ara-C Dose (mg/m2), Cycles | Patients, n (%) | Mean (SD) Ara-C Dose (mg/m2), Cycles | Patients, n (%) | Mean (SD) Ara-C Dose (mg/m2), Cycles | Patients, n (%) | Mean (SD) Ara-C Dose (mg/m2), Cycles | |
| Induction | 853 (100) | 432 (100) | 109 (100) | 312 (100) | ||||
| DAb | 602 (70.6) | 166.1 (289.5), 1.0 (0.1) | 341 (78.9) | 154.3 (232.3), 1.0 (0.0) | 91 (83.5) | 147.8 (222.4), 1.0 (0.1) | 170 (54.5) | 199.3 (401.5), 1.0 (0.0) |
| IAc | 133 (15.6) | 118.8 (16.5), 1.1 (0.3) | 92 (21.3) | 117.9 (15.7), 1.1 (0.3) | 26 (23.9) | 119.9 (18.6), 1.1 (0.4) | 15 (4.8) | 122.8 (18.1), 1.0 (0.0) |
| HAD | 126 (14.8) | 233.1 (362.9), 1.0 (0.2) | 4 (0.9) | 120.7 (8.6), 1.0 (0.0) | 2 (1.8) | 119.3 (3.1), 1.0 (0.0) | 120 (38.5) | 238.7 (370.9), 1.0 (0.2) |
| MA | 61 (7.2) | 107.4 (22.8), 1.0 (0.0) | 30 (6.9) | 106.6 (25.6), 1.0 (0.0) | 5 (4.6) | 126.2 (10.3), 1.0 (0.0) | 26 (8.3) | 104.7 (19.7), 1.0 (0.0) |
| Otherd | 140 (16.4) | – | 83 (19.2) | – | 25 (22.9) | – | 40 (12.8) | – |
| Consolidation | 743 (87.1) | 371 (85.9) | 97 (89.0) | 275 (88.1) | ||||
| HiDAC | 469 (63.1) | 6004.0 (323.3), 2.6 (0.6) | 245 (66.0) | 6021.1 (322.7), 2.6 (0.7) | 62 (63.9) | 6042.8 (235.0), 2.6 (0.7) | 162 (58.9) | 5964.4 (348.5), 2.7 (0.6) |
| MA | 236 (31.8) | 495.4 (979.4), 1.9 (0.8) | 78 (21.0) | 140.5 (303.3), 1.4 (0.6) | 14 (14.4) | 229.9 (445.7), 1.4 (0.5) | 144 (52.4) | 659.5 (1134.4), 2.1 (0.9) |
| DA | 216 (29.1) | 582.8 (1083.4), 1.6 (0.5) | 92 (24.8) | 138.1 (250.6), 1.8 (0.5) | 20 (20.6) | 119.0 (15.1), 1.7 (0.5) | 104 (37.8) | 1131.6 (1416.8), 1.5 (0.5) |
| MiDAC | 124 (16.7) | 2346.1 (799.6), 1.9 (0.5) | 71 (19.1) | 2314.8 (811.5), 2.0 (0.6) | 13 (13.4) | 2395.0 (805.6), 1.8 (0.4) | 40 (14.5) | 2386.9 (785.5), 1.9 (0.4) |
| HA | 108 (14.5) | 112.9 (36.2), 1.7 (0.6) | 52 (14.0) | 113.1 (48.8), 1.7 (0.5) | 7 (7.2) | 119.3 (10.6), 1.7 (0.5) | 49 (17.8) | 111.8 (19.8), 1.8 (0.6) |
| Ara-C+HDAC | 67 (9.0) | 5851.6 (526.5), 2.0 (0.7) | 41 (11.1) | 5921.0 (404.8), 1.8 (0.7) | 8 (8.2) | 6044.8 (149.9), 1.9 (0.8) | 18 (6.5) | 5651.0 (729.2), 2.2 (0.7) |
| Decitabine | 62 (8.3) | -, 2.5 (1.5) | 33 (8.9) | -, 2.5 (1.6) | 5 (5.2) | -, 3.4 (1.7) | 24 (8.7) | -, 2.1 (1.0) |
| IA | 62 (8.1) | 183.8 (325.9), 1.1 (0.2) | 47 (12.7) | 167.1 (266.5), 1.0 (0.2) | 8 (8.2) | 116.5 (18.5), 1.0 (0.0) | 7 (2.5) | 351.3 (663.1), 1.2 (0.5) |
| AA | 60 (8.1) | 105.8 (45.3), 1.5 (0.5) | 34 (9.2) | 113.1 (52.5), 1.5 (0.5) | 6 (6.2) | 115.8 (23.1), 1.7 (0.5) | 20 (7.3) | 90.1 (32.7), 1.5 (0.5) |
| Otherd | 234 (31.5) | - | 117 (31.5) | - | 20 (20.6) | - | 75 (27.3) | - |
| HSCT | ||||||||
| Allogeneic | 62 (7.3) | - | 32 (7.4) | - | 12 (11.0) | - | 18 (5.8) | - |
| Autologous | 1 (0.1) | - | 1 (0.2) | - | 0 | - | 0 | - |
| (b) | ||||||||
| Therapy | All Patients with R/R AML (N = 289) | FLT3WT at R/R Diagnosis (N = 58) | FLT3MUT at R/R Diagnosis (N = 14) | Unknown FLT3 Mutation Status (N = 217) | ||||
| Patients,a n (%) | Mean (SD) Ara-C Dose (mg/m2), Cycles | Patients, n (%) | Mean (SD) Ara-C Dose (mg/m2), Cycles | Patients, n (%) | Mean (SD) Ara-C Dose (mg/m2), Cycles | Patients, n (%) | Mean (SD) Ara-C Dose (mg/m2), Cycles | |
| Induction | 289 (100) | 58 (100) | 14 (100) | 217 (100) | ||||
| DAb | 213 (73.7) | 182 (355.3), 1.0 (0.0) | 48 (82.8) | 201.8 (332.5), 1.0 (0.0) | 10 (71.4) | 121.1 (8.1), 1.0 (0.0) | 155 (71.4) | 180.6 (373.8), 1.0 (0.0) |
| IAc | 50 (17.3) | 116.6 (15.3), 1.2 (0.4) | 7 (12.1) | 112.0 (6.0), 1.2 (0.5) | 2 (14.3) | 121.7 (8.0), 1.0 (0.0) | 41 (18.9) | 117.2 (16.6), 1.2 (0.4) |
| HAD | 43 (14.9) | 199.3 (308.8), 1.0 (0.2) | 3 (5.2) | 104.4 (8.2), 1.0 (0.0) | 2 (14.3) | 111.0 (9.7), 1.0 (0.0) | 38 (17.5) | 208.7 (323.2), 1.1 (0.2) |
| MA | 30 (10.4) | 109.8 (20.1), 1.0 (0.0) | 6 (10.3) | 110.9 (17.9), 1.0 (0.0) | 1 (7.1) | 104.1 (-), 1.0 (-) | 23 (10.6) | 109.7 (21.5), 1.0 (0.0) |
| D-AA | 16 (5.5) | 48.5 (16.7), 1.1 (0.3) | 0 | - | 0 | - | 16 (7.4) | 48.5 (16.7), 1.1 (0.3) |
| Otherd | 33 (11.4) | - | 4 (6.9) | - | 1 (7.1) | - | 26 (12.0) | - |
| Consolidation | 230 (79.6) | 55 (94.8) | 12 (85.7) | 163 (75.1) | ||||
| HiDAC | 134 (58.3) | 5979.1 (325.1), 2.7 (0.6) | 35 (63.6) | 5980.4 (315.4), 2.7 (0.6) | 8 (66.7) | 5985.1 (301.4), 2.8 (0.4) | 91 (55.8) | 5977.9 (332.5), 2.6 (0.7) |
| MA | 80 (34.8) | 528.0 (1015.6), 1.8 (0.8) | 14 (25.5) | 273.6 (662.1), 1.7 (0.9) | 4 (33.3) | 112.6 (9.2), 1.4 (0.5) | 62 (38.0) | 592.0 (1079.9), 1.8 (0.7) |
| DAb | 68 (29.6) | 655.5 (1146.5), 1.6 (0.6) | 15 (27.3) | 250.3 (589.8), 1.6 (0.5) | 0 | - | 53 (32.5) | 768.1 (1238.0), 1.6 (0.6) |
| MiDAC | 43 (18.7) | 2175.4 (724.6), 1.9 (0.5) | 10 (18.2) | 1961.5 (172.2), 2.1 (0.4) | 1 (8.3) | 4165.8 (-), 2.0 (-) | 32 (19.6) | 2185.4 (759.5), 1.8 (0.5) |
| HA | 34 (14.8) | 121.8 (37.7), 1.7 (0.6) | 9 (16.4) | 148.5 (50.7), 1.9 (0.3) | 1 (8.3) | 117.8 (-), 2.0 (-) | 24 (14.7) | 111.0 (26.0), 1.6 (0.6) |
| Decitabine | 20 (8.7) | -, 1.9 (1.1) | 3 (5.5) | -, 1.0 (0.0) | 1 (8.3) | -, 3.0 (-) | 16 (9.8) | -, 1.8 (1.1) |
| Ara-C+HDAC | 18 (7.8) | 5915.5 (397.5), 1.8 (0.6) | 2 (3.6) | 5613.8 (284.9), 1.0 (0.0) | 1 (8.3) | 6095.8 (-), 1.0 (-) | 15 (9.2) | 5932.4 (406.3), 1.9 (0.6) |
| AA | 17 (7.4) | 106.3 (52.8), 1.6 (0.5) | 3 (5.5) | 175.4 (49.4), 1.8 (0.4) | 0 | - | 14 (8.6) | 88.1 (36.7), 1.5 (0.5) |
| IAc | 14 (6.1) | 135.5 (61.1), 1.0 (0.0) | 4 (7.3) | 187.5 (50.1), 1.0 (0.0) | 0 | - | 10 (6.1) | 114.7 (53.7), 1.0 (0.0) |
| Otherd | 60 (26.1) | - | 11 (20.0) | - | 1 (8.3) | - | 34 (20.9) | - |
| HSCT | - | |||||||
| Allogeneic | 12 (4.2) | - | 1 (1.7) | - | 2 (14.3) | - | 9 (4.1) | - |
| Autologous | 0 | - | 0 | - | 0 | - | 0 | - |
Notes: aTreatment information was summarized for each regimen and categorized by therapy type. This column summarizes the number of patients who ever received a specific treatment regimen. A patient receiving multiple treatment regimens under one treatment type would be counted for each received treatment regimen; therefore, the percentages under each treatment type may not add up to 100%; bDA regimen included DA 7+3, DA 5+2, and other DA. DA 7+3 refers to cytarabine daily for 7 days and daunorubicin daily for 3 days. DA 5+2 refers to cytarabine daily for 5 days and daunorubicin daily for 2 days; cIA regimen included IA 7+3, IA 5+2, and other IA. IA 7+3 refers to cytarabine daily for 7 days and idarubicin daily for 3 days. IA 5+2 refers to cytarabine daily for 5 days and idarubicin daily for 2 days; dOther refers to a combined group of individual regimens used by <5% of patients.
Abbreviations: AA, cytarabine and aclarubicin; AML, acute myeloid leukemia; Ara-C, cytarabine; Ara-C+HDAC, cytarabine and histone deacetylase; DA, daunorubicin and cytarabine; D-AA, decitabine, cytarabine, and aclarubicin; FLT3, FMS-like tyrosine kinase-3; HA, homoharringtonine and cytarabine; HAD, homoharringtonine, cytarabine, and daunorubicin; HSCT, hematopoietic stem-cell transplantation; HiDAC, high-dose cytarabine; IA, idarubicin and cytarabine; MA, cytarabine and mitoxantrone; MiDAC, mid-dose cytarabine; MUT, mutated; ND, newly diagnosed; SD, standard deviation; WT, wild type.